Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2.

Eitemau Tebyg

• Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.
  gan: Lissoni, P., et al.
  Cyhoeddwyd: (1993)
• Serum interleukin-2 levels in relation to the neuroendocrine status in cancer patients.
  gan: Lissoni, P., et al.
  Cyhoeddwyd: (1990)
• A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
  gan: Lissoni, P., et al.
  Cyhoeddwyd: (1994)
• Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumours.
  gan: Lissoni, P., et al.
  Cyhoeddwyd: (1989)
• Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
  gan: Lissoni, P., et al.
  Cyhoeddwyd: (1992)